Cargando…
Bacteriophage Therapy: Developments and Directions
In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148498/ https://www.ncbi.nlm.nih.gov/pubmed/32213955 http://dx.doi.org/10.3390/antibiotics9030135 |
_version_ | 1783520606424137728 |
---|---|
author | Nikolich, Mikeljon P. Filippov, Andrey A. |
author_facet | Nikolich, Mikeljon P. Filippov, Andrey A. |
author_sort | Nikolich, Mikeljon P. |
collection | PubMed |
description | In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these infections. Among the potential antibacterial solutions are bacteriophage therapeutics, which possess very different properties from broad spectrum antibiotics that are currently the standard of care, and which can be used in combination with them and often provide synergies. In this review we summarize the state of the development of bacteriophage therapeutics and discuss potential paths to the implementation of phage therapies in contemporary medicine, focused on fixed phage cocktail therapeutics since these are likely to be the first bacteriophage products licensed for broad use in Western countries. |
format | Online Article Text |
id | pubmed-7148498 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71484982020-04-20 Bacteriophage Therapy: Developments and Directions Nikolich, Mikeljon P. Filippov, Andrey A. Antibiotics (Basel) Review In an era of proliferating multidrug resistant bacterial infections that are exhausting the capacity of existing chemical antibiotics and in which the development of new antibiotics is significantly rarer, Western medicine must seek additional therapeutic options that can be employed to treat these infections. Among the potential antibacterial solutions are bacteriophage therapeutics, which possess very different properties from broad spectrum antibiotics that are currently the standard of care, and which can be used in combination with them and often provide synergies. In this review we summarize the state of the development of bacteriophage therapeutics and discuss potential paths to the implementation of phage therapies in contemporary medicine, focused on fixed phage cocktail therapeutics since these are likely to be the first bacteriophage products licensed for broad use in Western countries. MDPI 2020-03-24 /pmc/articles/PMC7148498/ /pubmed/32213955 http://dx.doi.org/10.3390/antibiotics9030135 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nikolich, Mikeljon P. Filippov, Andrey A. Bacteriophage Therapy: Developments and Directions |
title | Bacteriophage Therapy: Developments and Directions |
title_full | Bacteriophage Therapy: Developments and Directions |
title_fullStr | Bacteriophage Therapy: Developments and Directions |
title_full_unstemmed | Bacteriophage Therapy: Developments and Directions |
title_short | Bacteriophage Therapy: Developments and Directions |
title_sort | bacteriophage therapy: developments and directions |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148498/ https://www.ncbi.nlm.nih.gov/pubmed/32213955 http://dx.doi.org/10.3390/antibiotics9030135 |
work_keys_str_mv | AT nikolichmikeljonp bacteriophagetherapydevelopmentsanddirections AT filippovandreya bacteriophagetherapydevelopmentsanddirections |